HK1166700A1 - 用於癌症治療的選擇性 受體拮抗性物質 - Google Patents

用於癌症治療的選擇性 受體拮抗性物質

Info

Publication number
HK1166700A1
HK1166700A1 HK12107420.1A HK12107420A HK1166700A1 HK 1166700 A1 HK1166700 A1 HK 1166700A1 HK 12107420 A HK12107420 A HK 12107420A HK 1166700 A1 HK1166700 A1 HK 1166700A1
Authority
HK
Hong Kong
Prior art keywords
cancer
selective
treatment
receptor antagonistic
antagonistic substance
Prior art date
Application number
HK12107420.1A
Other languages
English (en)
Inventor
Yukinori Take
Shinichi Koizumi
Takako Okumura
Kazuhiko Nonomura
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of HK1166700A1 publication Critical patent/HK1166700A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12107420.1A 2009-04-22 2012-07-30 用於癌症治療的選擇性 受體拮抗性物質 HK1166700A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009104568 2009-04-22
JP2010015445 2010-01-27
PCT/JP2010/057114 WO2010123049A1 (ja) 2009-04-22 2010-04-22 癌治療のための選択的ｅｐ４受容体拮抗物質

Publications (1)

Publication Number Publication Date
HK1166700A1 true HK1166700A1 (zh) 2012-11-09

Family

ID=43011165

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102723.2A HK1214763A1 (zh) 2009-04-22 2012-07-30 癌症治療用選擇性 受體拮抗物質
HK12107420.1A HK1166700A1 (zh) 2009-04-22 2012-07-30 用於癌症治療的選擇性 受體拮抗性物質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16102723.2A HK1214763A1 (zh) 2009-04-22 2012-07-30 癌症治療用選擇性 受體拮抗物質

Country Status (12)

Country Link
US (5) US8921391B2 (zh)
EP (3) EP2965756B1 (zh)
JP (1) JP5668219B2 (zh)
KR (1) KR101575706B1 (zh)
CN (2) CN105596320B (zh)
BR (1) BRPI1014174B8 (zh)
CA (1) CA2754702C (zh)
ES (3) ES2562814T3 (zh)
HK (2) HK1214763A1 (zh)
MX (2) MX345032B (zh)
RU (1) RU2563817C2 (zh)
WO (1) WO2010123049A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
MA39906A (fr) * 2014-05-23 2017-03-01 Eisai R&D Man Co Ltd Polythérapies pour le traitement du cancer
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
JP2021530487A (ja) * 2018-07-11 2021-11-11 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその合成
US20210353648A1 (en) * 2018-09-27 2021-11-18 Arrys Therapeutics, Inc. Grapiprant unit dosage forms
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
CN114206866A (zh) * 2019-06-11 2022-03-18 泰昂治疗公司 前列腺素e2受体4拮抗剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054808A1 (fr) * 1999-03-16 2000-09-21 Toray Industries, Inc. Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
EP1442744B1 (en) * 1999-08-10 2006-12-20 Glaxo Group Limited EP4 receptor ligand and use against neuropathic pain, colon cancer, HIV and migrane
KR20020076330A (ko) * 2000-02-22 2002-10-09 오노 야꾸힝 고교 가부시키가이샤 안식향산 유도체, 이들의 제조 방법 및 이들을 유효성분으로서 함유하는 약제
US6710205B2 (en) 2000-02-22 2004-03-23 Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives, processes for producing the same and drugs containing the same as the active ingredient
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
EP1494667A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
EP1494669A1 (en) 2002-04-16 2005-01-12 Fujisawa Pharmaceutical Co., Ltd. Medicament for preventing and/or treating chronic rejection
RS20060143A (en) * 2003-09-03 2008-06-05 Pfizer Inc., Phenyl or pyridil amide compounds as prostaglandin e2 antagonists
WO2005102389A2 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
AU2005238291A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
BRPI0510598A (pt) * 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
ES2344310T3 (es) * 2005-03-11 2010-08-24 Raqualia Pharma Inc Formas cristalinas de un derivado de imidazol.
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
CA2754702C (en) * 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
KR101539436B1 (ko) 2013-12-30 2015-07-24 주식회사 효성 가스 절연 개폐기의 부분 방전 검출 장치

Also Published As

Publication number Publication date
EP2422779A1 (en) 2012-02-29
CN102421429A (zh) 2012-04-18
CN105596320A (zh) 2016-05-25
EP2422779B1 (en) 2016-01-06
US20170253595A1 (en) 2017-09-07
KR101575706B1 (ko) 2015-12-10
US20200188367A1 (en) 2020-06-18
BRPI1014174B8 (pt) 2021-05-25
MX345032B (es) 2017-01-12
EP3431085B1 (en) 2023-10-11
BRPI1014174B1 (pt) 2020-10-06
US10947235B2 (en) 2021-03-16
US10611761B2 (en) 2020-04-07
US11840530B2 (en) 2023-12-12
US20220073510A1 (en) 2022-03-10
EP2422779A4 (en) 2013-06-19
US20120088723A1 (en) 2012-04-12
JPWO2010123049A1 (ja) 2012-10-25
CN105596320B (zh) 2019-03-22
ES2960438T3 (es) 2024-03-04
WO2010123049A1 (ja) 2010-10-28
MX369117B (es) 2019-10-28
EP3431085A1 (en) 2019-01-23
US8921391B2 (en) 2014-12-30
RU2563817C2 (ru) 2015-09-20
CA2754702A1 (en) 2010-10-28
EP2965756B1 (en) 2018-10-10
EP2965756A1 (en) 2016-01-13
MX2011011058A (es) 2011-11-18
CN102421429B (zh) 2016-08-17
ES2698508T3 (es) 2019-02-05
HK1214763A1 (zh) 2016-08-05
EP3431085C0 (en) 2023-10-11
JP5668219B2 (ja) 2015-02-12
KR20120096402A (ko) 2012-08-30
ES2562814T3 (es) 2016-03-08
BRPI1014174A2 (pt) 2016-04-05
CA2754702C (en) 2016-06-07
US9688674B2 (en) 2017-06-27
US20150111920A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
HK1214763A1 (zh) 癌症治療用選擇性 受體拮抗物質
HK1199058A1 (zh) -樣受體和激動劑用於治療癌症的用途
HK1162916A1 (zh) 治療固體腫瘤的方法
EP2542081A4 (en) COMPOSITIONS FOR CANCER TREATMENT
IL219073A (en) A drug combination for cancer treatment
IL218575A0 (en) Treatment of cancer
IL229878A0 (en) Compounds for the treatment of cancer
EP2680853A4 (en) TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
IL227308A0 (en) Use of tlr receptor agonists for cancer treatment
ZA201201984B (en) Treating notch1- antagonist- resistant cancer (s)using notch3 antagonists
IL214746A0 (en) Substituted pyrimidines for the treatment of cancer
EP2330892A4 (en) TREATMENT PROCEDURE USING AMMONIA RECEIVER MEDICAMENTS
EP2608671A4 (en) COMPOUNDS USED IN THE TREATMENT OF CANCER
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
HK1174615A1 (zh) 用於治療惡病質的葛瑞林受體激動劑
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
IL213198A (en) Preparation for the treatment of primary thrombocythemia
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
IL222072A (en) Composition for the treatment of primary thrombocythemia
PL2391366T3 (pl) Podstawione benzimidazole do leczenia gwiaździaków
EP2264462A4 (en) METHOD FOR SCREENING A THERAPEUTIC AGENT FOR CANCER
GB0906222D0 (en) Methods for screening of therapeutic agents
GB0913427D0 (en) Compounds for treatment of imflammation
GB0921757D0 (en) Treatment of cancer
GB0906484D0 (en) Use of prostaganin for treatment of prostrate cancer

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM RAQUALIA PHARMA INC TO RAQUALIA PHARMA INC.